246 related articles for article (PubMed ID: 31641765)
1. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Lasko MJ; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
[TBL] [Abstract][Full Text] [Related]
3.
Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
[TBL] [Abstract][Full Text] [Related]
4. The Novel β-Lactam Enhancer Zidebactam Augments the
Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Gethers M; Chen I; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2022 Jun; 77(7):1931-1937. PubMed ID: 35411395
[TBL] [Abstract][Full Text] [Related]
6.
Lasko MJ; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
[TBL] [Abstract][Full Text] [Related]
7. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
[TBL] [Abstract][Full Text] [Related]
8. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Gill CM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
[TBL] [Abstract][Full Text] [Related]
9. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
10. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
[TBL] [Abstract][Full Text] [Related]
11. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
12. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the
Avery LM; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181365
[TBL] [Abstract][Full Text] [Related]
14.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
15. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852
[TBL] [Abstract][Full Text] [Related]
16.
Moya B; Barcelo IM; Cabot G; Torrens G; Palwe S; Joshi P; Umarkar K; Takalkar S; Periasamy H; Bhagwat S; Patel M; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782985
[TBL] [Abstract][Full Text] [Related]
17. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
18. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
[TBL] [Abstract][Full Text] [Related]
19. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A
J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659
[TBL] [Abstract][Full Text] [Related]
20. In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
Barceló I; Cabot G; Palwe S; Joshi P; Takalkar S; Periasamy H; Cortés-Lara S; Zamorano L; Sánchez-Diener I; Moya B; Bhagwat S; Patel M; Oliver A
J Antimicrob Chemother; 2021 Sep; 76(10):2546-2557. PubMed ID: 34219168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
